TrialTargeted oncology2022

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.

Tanya Trippett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.